Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Post-Mkt 05-06 18:50:08 EDT

4.78

+0.03

+0.63%

盘后4.71

-0.07-1.52%

18:28 EDT

High4.88	Low4.70	Vol997.26K
Open4.81	D1 Closing4.75	Amplitude3.79%
Mkt Cap669.20M	Tradable Cap460.87M	Total Shares140.00M
T/O4.76M	T/O Rate1.03%	Tradable Shares96.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":4.78,"timestamp":1778097600000,"preClose":4.75,"halted":0,"volume":997264,"hourTrading":{"tag":"盘后","latestPrice":4.7075,"preClose":4.78,"latestTime":"18:28 EDT","volume":2129,"amount":10175.0813717,"timestamp":1778106482131,"change":-0.0725,"changeRate":-0.015167,"amplitude":0.018828},"delay":0,"changeRate":0.006315789473684263,"floatShares":96417099,"shares":140000000,"eps":-0.53,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"05-06 18:50:08 EDT","open":4.81,"high":4.875,"low":4.695,"amount":4755550.7169664,"amplitude":0.037895,"askPrice":4.81,"askSize":100,"bidPrice":4.6,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-0.53,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1778112000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":4.75,"preHourTrading":{"tag":"盘前","latestPrice":4.78,"preClose":4.75,"latestTime":"09:28 EDT","volume":3398,"amount":16562.929165999998,"timestamp":1778074135645,"change":0.03,"changeRate":0.006316,"amplitude":0.025263},"postHourTrading":{"tag":"盘后","latestPrice":4.7075,"preClose":4.78,"latestTime":"18:28 EDT","volume":2129,"amount":10175.0813717,"timestamp":1778106482131,"change":-0.0725,"changeRate":-0.015167,"amplitude":0.018828},"volumeRatio":0.811724,"impliedVol":1.0786,"impliedVolPercentile":0.3187},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"2633858928","title":"Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633858928","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633858928?lang=en_us&edition=fundamental","pubTime":"2026-05-06 02:20","pubTimestamp":1778005200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 14:20 ET (18:20 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943141","title":"Aclaris Therapeutics Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943141","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943141?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:55","pubTimestamp":1777985700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 08:55 ET (12:55 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914974","title":"Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914974?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:58","pubTimestamp":1777978723,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin raised the firm’s price target on Aclaris Therapeutics (ACRS) to $11 from $7 and keeps an Overweight rating on the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-price-target-raised-to-11-from-7-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-price-target-raised-to-11-from-7-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969642","title":"Aclaris Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969642?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:40","pubTimestamp":1777927203,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Seamus Fernandez initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $12 price target Published first on The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963927","title":"Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963927?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924862,"startTime":"0","endTime":"0","summary":"Damora Therapeutics set May 1, 2026 as effective date for CFO Lori Firmani to step down.Senior Vice President, Finance Brian Burkavage will become principal financial officer and principal accounting officer at that time.Burkavage previously served as senior vice president, finance and chief accounting officer at IO Biotech from November 2021 to December 2025.Earlier roles included controller at Passage Bio, director of financial planning and analysis at Aclaris Therapeutics, and 11 years at Ernst & Young in audit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbYN4kT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ACRS","IOBTQ","DMRA","PASG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632956451","title":"Aclaris Therapeutics Inc  expected to post a loss of 16 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632956451","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632956451?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:37","pubTimestamp":1777901827,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc  expected to post a loss of16cents a share - Earnings Preview Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to  show a fall in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632933604","title":"JTL Industries Wins ACRS Nod, Tightens Grip on Global Structural Steel Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2632933604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632933604?lang=en_us&edition=fundamental","pubTime":"2026-05-04 14:12","pubTimestamp":1777875174,"startTime":"0","endTime":"0","summary":"JTL Industries Limited ( ($IN:JTLIND) ) has issued an update. JTL Industries has secured Product Conformity Certification from the Australasian Cer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jtl-industries-wins-acrs-nod-tightens-grip-on-global-structural-steel-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jtl-industries-wins-acrs-nod-tightens-grip-on-global-structural-steel-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","PICK","BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631413535","title":"Aclaris Therapeutics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2631413535","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631413535?lang=en_us&edition=fundamental","pubTime":"2026-04-30 00:13","pubTimestamp":1777479180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 12:13 ET (16:13 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631081519","title":"Aclaris Therapeutics price target raised to $10 from $8 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2631081519","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631081519?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:21","pubTimestamp":1777465279,"startTime":"0","endTime":"0","summary":"Wedbush analyst Martin Fan raised the firm’s price target on Aclaris Therapeutics (ACRS) to $10 from $8 and keeps an Outperform rating on the share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-price-target-raised-to-10-from-8-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-price-target-raised-to-10-from-8-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631590162","title":"Wedbush Raises Price Target on Aclaris Therapeutics to $10 From $8, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2631590162","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631590162?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:01","pubTimestamp":1777460483,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) has an average rating of buy and mean price target of $9.05 according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630305736","title":"Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630305736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630305736?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:21","pubTimestamp":1777375287,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) provided a clinical update on its biologic and oral inhibitor compounds including positive full top line results from t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-ati-052-antibody-shows-pk-efficacy-in-phase-1a-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-ati-052-antibody-shows-pk-efficacy-in-phase-1a-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4181","PK","ATI","IE00B19Z4B17.USD","BK4187","IE00B7SZL793.SGD","BK4006","ACRS","LU0963586101.USD","BK4218","IE00B66KJ199.SGD","LU1878469433.USD","BK4007","LU2065731478.USD","IE0031619046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630370715","title":"BRIEF-Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055","url":"https://stock-news.laohu8.com/highlight/detail?id=2630370715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630370715?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:32","pubTimestamp":1777372359,"startTime":"0","endTime":"0","summary":"BRIEF-Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055April 28 (Reuters) - Aclaris Therapeutics Inc ACRS.O:ACLARIS THERAPEUTICS ANNOUNCES POSITIVE FULL ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630704673","title":"Aclaris Therapeutics Inc - Enrollment Ongoing in Phase 1B Trials of ATI-052; Top Line Results Expected H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630704673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630704673?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:30","pubTimestamp":1777372221,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0HH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630370491","title":"Aclaris Therapeutics Inc - ATI-052 Well Tolerated With Favorable Safety Profile in Phase 1a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630370491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630370491?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:30","pubTimestamp":1777372221,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0HH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630110370","title":"Aclaris Therapeutics Inc: No Impact of Anti-Drug Antibodies (Ada) on Pk or Pd Has Been Observed in This Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630110370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630110370?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:30","pubTimestamp":1777372221,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0HH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630234627","title":"BML Capital’s Braden Leonard sells 300,000 Aclaris shares for $1.36 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2630234627","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630234627?lang=en_us&edition=fundamental","pubTime":"2026-04-28 07:27","pubTimestamp":1777332455,"startTime":"0","endTime":"0","summary":"Braden M. Leonard, 10% owner of Aclaris Therapeutics, disclosed sale of 300,000 common shares at $4.53 on April 23.Holdings reported through BML Investment Partners fell to 13,950,000 shares.Transaction was reported in a Form 4 filed April 27.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDLbzWHBZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BML Capital’s Braden Leonard sells 300,000 Aclaris shares for $1.36 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630831014","title":"Aclaris to release Phase 1a ATI-052 trial results April 28","url":"https://stock-news.laohu8.com/highlight/detail?id=2630831014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630831014?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:45","pubTimestamp":1777322723,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics set an April 28, 2026 premarket update to release full Phase 1a results from its ATI-052 anti-TSLP/IL-4R bispecific antibody trial.Results have not yet been presented, with disclosure scheduled ahead of US market open.Update will also cover outcome of lead indication selection process for ITK/JAK3 inhibitor ATI-2138, a step that can steer clinical development priorities.Management will discuss both programs on an 8:30 a.m. ET webcast with slides.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL5hBxHV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","NDAQ","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU2095319765.USD","BK4112","SG9999014013.SGD","SG9999014039.USD","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU0314104364.USD","BK4007","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210150020.SGD","ACRS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630310425","title":"Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630310425","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630310425?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:45","pubTimestamp":1777322700,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., April  27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflamma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3282070/37216/en/Aclaris-Therapeutics-to-Provide-Clinical-Update-on-Key-Biologic-and-Oral-Inhibitor-Programs-on-April-28-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629836987","title":"Aclaris Therapeutics announces upcoming annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629836987","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629836987?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:48","pubTimestamp":1776944902,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics scheduled virtual annual shareholder meeting for June 4, 2026.Ballot includes election of two directors to serve terms ending at 2029 annual meeting.Shareholders will also vote on advisory approval of named executive officer compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL4bCgV3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628217055","title":"Aclaris Therapeutics (ACRS) Gets a Buy from Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2628217055","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628217055?lang=en_us&edition=fundamental","pubTime":"2026-04-17 00:37","pubTimestamp":1776357469,"startTime":"0","endTime":"0","summary":"In a report released today, Adam Vogel from Craig-Hallum maintained a Buy rating on Aclaris Therapeutics, with a price target of $10.00. Vogel cove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aclaris-therapeutics-acrs-gets-a-buy-from-craig-hallum-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aclaris-therapeutics-acrs-gets-a-buy-from-craig-hallum-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":0.1256},{"period":"1month","weight":0.131},{"period":"3month","weight":0.3418},{"period":"6month","weight":1.0925},{"period":"1year","weight":2.7109},{"period":"ytd","weight":0.5781}],"compareEarnings":[{"period":"1week","weight":0.017},{"period":"1month","weight":0.1036},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.0798},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.0614}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.038718},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.021975},{"month":4,"riseRate":0.454545,"avgChangeRate":0.005147},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.03075},{"month":6,"riseRate":0.6,"avgChangeRate":-0.004956},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}